NASDAQ:PRTK - Paratek Pharmaceuticals Stock Price, Price Target & More

Get Started

$10.30 -0.10 (-0.96 %)

(As of 05/27/2018 05:28 AM ET)

Previous Close$10.30

Today's Range$10.15 - $10.40

52-Week Range$10.10 - $29.00

Volume583,130 shs

Average Volume622,790 shs

Market Capitalization$328.60 million

P/E Ratio-3.12

Dividend YieldN/A

Beta0.49

About Paratek Pharmaceuticals (NASDAQ:PRTK)

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Receive PRTK News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

SymbolNASDAQ:PRTK

CUSIP89354M10

Webwww.paratekpharma.com

Phone617-807-6600

Debt

Debt-to-Equity Ratio0.47

Current Ratio8.06

Quick Ratio8.06

Price-To-Earnings

Trailing P/E Ratio-3.12

Forward P/E Ratio-2.82

P/E GrowthN/A

Sales & Book Value

Annual Sales$12.62 million

Price / Sales25.79

Cash FlowN/A

Price / CashN/A

Book Value$3.51 per share

Price / Book2.93

Profitability

EPS (Most Recent Fiscal Year)($3.30)

Net Income$-89,060,000.00

Net Margins-707.08%

Return on Equity-87.29%

Return on Assets-50.20%

Miscellaneous

Employees83

Outstanding Shares31,600,000

Paratek Pharmaceuticals (NASDAQ:PRTK) Frequently Asked Questions

What is Paratek Pharmaceuticals' stock symbol?

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) posted its quarterly earnings data on Wednesday, May, 9th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, beating analysts' consensus estimates of ($0.94) by $0.03. The specialty pharmaceutical company earned $0.01 million during the quarter, compared to analyst estimates of $0.02 million. Paratek Pharmaceuticals had a negative net margin of 707.08% and a negative return on equity of 87.29%. View Paratek Pharmaceuticals' Earnings History.

What price target have analysts set for PRTK?

7 brokers have issued 1 year target prices for Paratek Pharmaceuticals' shares. Their forecasts range from $36.00 to $55.00. On average, they anticipate Paratek Pharmaceuticals' stock price to reach $45.00 in the next year. View Analyst Ratings for Paratek Pharmaceuticals.

Are investors shorting Paratek Pharmaceuticals?

Paratek Pharmaceuticals saw a increase in short interest in the month of April. As of April 30th, there was short interest totalling 4,049,664 shares, an increase of 61.9% from the April 13th total of 2,500,701 shares. Based on an average trading volume of 1,122,559 shares, the short-interest ratio is currently 3.6 days. Currently, 15.7% of the company's shares are sold short.

Who are some of Paratek Pharmaceuticals' key competitors?

Some companies that are related to Paratek Pharmaceuticals include Radius Health (RDUS), Uniqure (QURE), Epizyme (EPZM), WAVE Life Sciences (WVE), Theravance Biopharma (TBPH), Immuron (IMRN), Intra-Cellular Therapies (ITCI), Retrophin (RTRX), Mirati Therapeutics (MRTX), Apellis Pharmaceuticals (APLS), Revance Therapeutics (RVNC), Zai Lab (ZLAB), Alder BioPharmaceuticals (ALDR), Dynavax Technologies (DVAX) and TG Therapeutics (TGTX).

Who are Paratek Pharmaceuticals' key executives?

Paratek Pharmaceuticals' management team includes the folowing people:

Mr. Michael F. Bigham, Chairman & CEO (Age 60)
Dr. Evan Loh, Pres, Chief Medical Officer, COO & Director (Age 59)
Mr. Douglas W. Pagán, Chief Financial Officer (Age 46)
Mr. William M. Haskel, Sr. VP, Gen. Counsel & Corp. Sec. (Age 56)
Mr. Adam Woodrow, Chief Commercial Officer and VP (Age 51)

Has Paratek Pharmaceuticals been receiving favorable news coverage?

Headlines about PRTK stock have trended somewhat positive recently, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Paratek Pharmaceuticals earned a daily sentiment score of 0.14 on Accern's scale. They also assigned media headlines about the specialty pharmaceutical company an impact score of 45.43 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Paratek Pharmaceuticals' major shareholders?

Paratek Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.42%), Highland Capital Management LP (3.04%), C WorldWide Group Holding A S (1.58%), Northern Trust Corp (1.14%), Water Island Capital LLC (0.81%) and JPMorgan Chase & Co. (0.72%). Company insiders that own Paratek Pharmaceuticals stock include Adam Woodrow, Douglas W Pagan, Evan Loh, Fund Iv LP Omega, Michael Bigham and Robert S Radie. View Institutional Ownership Trends for Paratek Pharmaceuticals.

Which institutional investors are selling Paratek Pharmaceuticals stock?

PRTK stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, C WorldWide Group Holding A S, Prosight Management LP, JPMorgan Chase & Co. and Opus Point Partners Management LLC. Company insiders that have sold Paratek Pharmaceuticals company stock in the last year include Adam Woodrow, Douglas W Pagan, Evan Loh, Michael Bigham and Robert S Radie. View Insider Buying and Selling for Paratek Pharmaceuticals.

Which institutional investors are buying Paratek Pharmaceuticals stock?

PRTK stock was purchased by a variety of institutional investors in the last quarter, including Highland Capital Management LP, Omni Partners LLP, BlackRock Inc., California Public Employees Retirement System, Water Island Capital LLC, A.R.T. Advisors LLC, Trellus Management Company LLC and Northern Trust Corp. Company insiders that have bought Paratek Pharmaceuticals stock in the last two years include Fund Iv LP Omega and Michael Bigham. View Insider Buying and Selling for Paratek Pharmaceuticals.

How do I buy shares of Paratek Pharmaceuticals?

Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Paratek Pharmaceuticals' stock price today?

One share of PRTK stock can currently be purchased for approximately $10.30.

How big of a company is Paratek Pharmaceuticals?

Paratek Pharmaceuticals has a market capitalization of $328.60 million and generates $12.62 million in revenue each year. The specialty pharmaceutical company earns $-89,060,000.00 in net income (profit) each year or ($3.30) on an earnings per share basis. Paratek Pharmaceuticals employs 83 workers across the globe.

How can I contact Paratek Pharmaceuticals?

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected]

MarketBeat Community Rating for Paratek Pharmaceuticals (PRTK)

Community Ranking:		2.9 out of 5 ( )
Outperform Votes:		272 (Vote Outperform)
Underperform Votes:		203 (Vote Underperform)
Total Votes:		475

MarketBeat's community ratings are surveys of what our community members think about Paratek Pharmaceuticals and other stocks. Vote "Outperform" if you believe PRTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTK will underperform the S&P 500 over the long term. You may vote once every thirty days.

Paratek Pharmaceuticals (NASDAQ:PRTK) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

7 Wall Street analysts have issued ratings and price targets for Paratek Pharmaceuticals in the last 12 months. Their average twelve-month price target is $45.00, suggesting that the stock has a possible upside of 336.89%. The high price target for PRTK is $55.00 and the low price target for PRTK is $36.00. There are currently 7 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.14	3.14
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 7 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 7 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 6 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 6 Buy Rating(s) 1 Strong Buy Rating(s)
Consensus Price Target:	$45.00	$45.00	$42.7143	$42.7143
Price Target Upside:	336.89% upside	242.21% upside	128.42% upside	91.12% upside

Paratek Pharmaceuticals (NASDAQ:PRTK) Consensus Price Target History

Price Target History for Paratek Pharmaceuticals (NASDAQ:PRTK)

Paratek Pharmaceuticals (NASDAQ:PRTK) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/9/2018	Cantor Fitzgerald	Set Price Target	Buy	$50.00	Low
3/4/2018	Leerink Swann	Reiterated Rating	Outperform		Low
3/2/2018	HC Wainwright	Boost Price Target	Buy ➝ Buy	$43.00 ➝ $55.00	High
3/2/2018	Raymond James	Reiterated Rating	Strong-Buy ➝ Outperform	$36.00	High
3/2/2018	UBS	Downgrade	Strong-Buy ➝ Outperform		High
10/24/2017	Robert W. Baird	Reiterated Rating	Buy	$40.00	N/A
10/24/2017	Guggenheim	Initiated Coverage	Buy	$44.00	N/A
4/4/2017	BTIG Research	Boost Price Target	Buy	$47.00 ➝ $56.00	Medium
4/3/2017	Wedbush	Reiterated Rating	Outperform ➝ Outperform	$30.00	High
6/17/2016	Ladenburg Thalmann	Boost Price Target	Buy	$46.00 ➝ $52.00	N/A

(Data available from 5/27/2016 forward)

Paratek Pharmaceuticals (NASDAQ:PRTK) Earnings History and Estimates Chart

Earnings by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Paratek Pharmaceuticals (NASDAQ:PRTK) Earnings Estimates

2018 EPS Consensus Estimate: ($3.63)
2019 EPS Consensus Estimate: ($4.89)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	($0.91)	($0.86)	($0.89)
Q2 2018	2	($0.94)	($0.90)	($0.92)
Q3 2018	2	($0.98)	($0.48)	($0.73)
Q4 2018	2	($1.16)	($1.02)	($1.09)
Q1 2019	2	($3.54)	($0.85)	($2.20)
Q2 2019	1	($0.88)	($0.88)	($0.88)
Q3 2019	1	($0.89)	($0.89)	($0.89)
Q4 2019	1	($0.92)	($0.92)	($0.92)

Paratek Pharmaceuticals (NASDAQ PRTK) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/9/2018	Q1	($0.94)	($0.91)	$0.02 million	$0.01 million	View	Listen
3/1/2018	Q4 2017	($0.75)	($0.7840)	$5.00 million	$5.07 million	View	N/A
11/8/2017	Q3 2017	($0.93)	($0.77)		$0.01 million	View	N/A
8/2/2017	Q2 2017	($0.89)	($0.64)	$7.50 million	$7.51 million	View	Listen
5/4/2017	Q1 2017	($1.2010)	($1.14)		$0.02 million	View	Listen
3/2/2017	Q4 2016	($1.3290)	($1.1650)		$0.03 million	View	Listen
11/2/2016		($1.38)	($1.04)			View	N/A
8/4/2016	Q2 2016	($1.66)	($1.69)			View	N/A
5/2/2016		($1.25)	($1.77)			View	N/A
2/23/2016	Q4	($1.18)	($1.20)			View	Listen
11/12/2015	Q315	($0.91)	($1.33)			View	Listen
8/5/2015	Q215	($0.75)	($0.94)	$3.62 billion		View	N/A
5/15/2015	Q1 2015	($2.16)	($0.96)			View	N/A
4/2/2015	Q1	($2.16)	($0.74)	$0.13 million	$4.00 million	View	N/A
5/5/2014		($0.18)	($0.15)		$0.42 million	View	N/A
3/13/2014	Q413	($0.21)	($0.29)	$0.50 million	$0.3160 million	View	N/A
11/7/2013	Q3 2013	($2.52)	($3.00)	$0.10 million	$0.38 million	View	N/A
8/7/2013	Q2 2013	($3.48)	($2.40)		$0.20 million	View	N/A
5/8/2013	Q1 2013	($0.42)	($0.56)		($5.83) million	View	N/A
2/27/2013	Q4 2012	($3.12)	($4.20)			View	N/A
11/12/2012	Q312	$0.06	$0.25	$8.37 million	$10.44 million	View	N/A
8/13/2012	Q2 2012	($3.60)	($3.60)			View	N/A
5/14/2012	Q1 2012	($5.28)	($4.47)			View	N/A
3/14/2012	Q4 2011	$4.20	$4.42			View	N/A
11/10/2011	Q3 2011	($4.92)	($4.43)			View	N/A
8/11/2011	Q2 2011	($3.36)	($2.04)			View	N/A
5/16/2011	Q1 2011	($3.24)	($1.68)			View	N/A
3/16/2011	Q4 2010	($3.36)	($2.35)			View	N/A
11/11/2010	Q3 2010	($2.64)	($2.47)			View	N/A
8/9/2010	Q2 2010	($1.80)	($1.85)			View	N/A
5/12/2010	Q1 2010	($2.04)	($1.66)			View	N/A
3/23/2010	Q4 2009	($2.76)	($2.11)			View	N/A
11/12/2009	Q3 2009	($0.12)	($3.47)			View	N/A
8/14/2009	Q2 2009		($6.53)			View	N/A
5/13/2009	Q1 2009		($11.38)			View	N/A
3/23/2009	Q4 2008		($15.71)			View	N/A
11/10/2008	Q3 2008		($15.97)			View	N/A
5/12/2008	Q1 2008	($13.21)	($2.76)			View	N/A
3/17/2008	Q4 2007	($5.40)	($6.24)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Paratek Pharmaceuticals (NASDAQ:PRTK) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/14/2014	special	$1.33		6/4/2014	5/26/2014	6/3/2014

(Data available from 1/1/2013 forward)

Paratek Pharmaceuticals (NASDAQ PRTK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.20%
Institutional Ownership Percentage: 77.40%

Insider Trading History for Paratek Pharmaceuticals (NASDAQ:PRTK)

Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Paratek Pharmaceuticals (NASDAQ PRTK) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/9/2018	Adam Woodrow	VP	Sell	5,700	$12.70	$72,390.00	89,167
4/9/2018	Douglas W Pagan	CFO	Sell	5,237	$12.70	$66,509.90	77,083
4/9/2018	Evan Loh	COO	Sell	8,084	$12.70	$102,666.80	214,786
4/9/2018	Michael Bigham	Chairman	Sell	8,700	$12.70	$110,490.00	199,730
2/6/2018	Adam Woodrow	VP	Sell	14,333	$13.87	$198,798.71	62,367
2/5/2018	Douglas W Pagan	CFO	Sell	16,291	$14.22	$231,658.02	39,570
2/5/2018	Evan Loh	COO	Sell	3,040	$14.22	$43,228.80	144,870
2/5/2018	Michael Bigham	Chairman	Sell	4,000	$14.22	$56,880.00	123,680
2/5/2018	Robert S Radie	Director	Sell	3,000	$14.22	$42,660.00	9,330
7/5/2017	Adam Woodrow	VP	Sell	3,800	$23.58	$89,604.00	69,500
7/5/2017	Douglas W Pagan	CFO	Sell	4,139	$23.58	$97,597.62	60,000
7/5/2017	Evan Loh	COO	Sell	4,351	$23.58	$102,596.58	112,783
7/5/2017	Michael Bigham	Chairman	Sell	5,075	$23.58	$119,668.50	109,500
6/19/2017	Douglas W Pagan	CFO	Sell	4,595	$25.00	$114,875.00	51,000
2/6/2017	Douglas W Pagan	CFO	Sell	3,405	$15.09	$51,381.45	58,983
2/6/2017	Evan Loh	COO	Sell	3,106	$15.09	$46,869.54	102,873
2/6/2017	Michael Bigham	Chairman	Sell	5,000	$15.09	$75,450.00	99,970
6/27/2016	Fund Iv L.P. Omega	Major Shareholder	Buy	461,538	$13.00	$5,999,994.00
6/23/2016	Michael Bigham	CEO	Buy	20,000	$13.45	$269,000.00	100,000
12/11/2015	Evan Loh	CMO	Buy	2,300	$16.87	$38,801.00	80,389
5/29/2015	Hbm Healthcare Investments (Ca	Major Shareholder	Sell	20,580	$30.75	$632,835.00
12/13/2013	Roumell Asset Management, Llc	major shareholder	Sell	1,470	$3.54	$5,203.80
12/11/2013	Roumell Asset Management, Llc	major shareholder	Sell	10,490	$3.55	$37,239.50
12/6/2013	Roumell Asset Management, Llc	major shareholder	Sell	8,710	$3.54	$30,833.40
12/4/2013	Roumell Asset Management, Llc	major shareholder	Sell	7,120	$3.50	$24,920.00
11/20/2013	Roumell Asset Management, Llc	major shareholder	Sell	10,040	$3.57	$35,842.80
11/12/2013	Roumell Asset Management, Llc	major shareholder	Sell	7,190	$3.53	$25,380.70
11/7/2013	Roumell Asset Management, Llc	major shareholder	Sell	4,960	$3.61	$17,905.60
10/30/2013	Roumell Asset Management, Llc	Major Shareholder	Sell	7,020	$3.69	$25,903.80

(Data available from 1/1/2013 forward)

Paratek Pharmaceuticals (NASDAQ PRTK) News Headlines

Source:

Date	Headline
	Paratek Pharmaceuticals (PRTK) Reports New Analysis Highlighting Efficacy of Omadacycline in Treating Community ... www.streetinsider.com - May 24 at 4:45 PM
	Cantor Fitzgerald Research Analysts Cut Earnings Estimates for Paratek Pharmaceuticals, Inc. (PRTK) www.americanbankingnews.com - May 24 at 8:22 AM
	Paratek Presents New Analysis Highlighting Efficacy of Omadacycline in Treating Community-Acquired Bacterial Pneumonia by Measures of Disease Severity finance.yahoo.com - May 22 at 4:34 PM
	What Investors Should Know About Paratek Pharmaceuticals Inc’s (NASDAQ:PRTK) Financial Strength finance.yahoo.com - May 21 at 4:36 PM
	Equities Analysts Issue Forecasts for Paratek Pharmaceuticals, Inc.'s Q2 2018 Earnings (PRTK) www.americanbankingnews.com - May 21 at 1:04 AM
	Gabelli Research Analysts Decrease Earnings Estimates for Paratek Pharmaceuticals, Inc. (PRTK) www.americanbankingnews.com - May 14 at 5:11 AM
	Paratek Pharmaceuticals, Inc. (PRTK) to Post Q2 2018 Earnings of ($0.94) Per Share, Leerink Swann Forecasts www.americanbankingnews.com - May 14 at 1:56 AM
	Paratek Pharmaceuticals, Inc. (PRTK) Receives Average Rating of "Buy" from Brokerages www.americanbankingnews.com - May 13 at 3:33 AM
	Paratek Pharmaceuticals, Inc. (PRTK) Sees Significant Growth in Short Interest www.americanbankingnews.com - May 12 at 1:06 AM
	Paratek Pharmaceuticals (PRTK) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS www.americanbankingnews.com - May 10 at 4:46 PM
	Edited Transcript of PRTK earnings conference call or presentation 9-May-18 12:30pm GMT finance.yahoo.com - May 10 at 9:27 AM
	Paratek Pharmaceuticals (PRTK) PT Set at $50.00 by Cantor Fitzgerald www.americanbankingnews.com - May 9 at 6:23 PM
	Paratek Pharmaceuticals' (PRTK) CEO Michael Bigham on Q1 2018 Results - Earnings Call Transcript seekingalpha.com - May 9 at 4:43 PM
	Paratek up 1% on Q1 result seekingalpha.com - May 9 at 9:17 AM
	5 Biotech Stocks Set to Beat Estimates This Earnings Season finance.yahoo.com - May 9 at 9:17 AM
	Paratek: 1Q Earnings Snapshot finance.yahoo.com - May 9 at 9:17 AM
	Paratek Pharmaceuticals Reports First Quarter 2018 Financial Results finance.yahoo.com - May 9 at 9:17 AM
	Is Paratek Pharmaceuticals Oversold? seekingalpha.com - May 3 at 9:06 AM
	Paratek Pharmaceuticals, Inc. (PRTK) Short Interest Update www.americanbankingnews.com - April 29 at 3:12 AM
	Paratek Pharmaceuticals to Report First Quarter 2018 Financial Results on May 9, 2018 finance.yahoo.com - April 26 at 9:03 AM
	Paratek Pharmaceuticals Presents Data Supporting Potential Approval of Omadacycline for Treatment of Community ... globenewswire.com - April 25 at 4:47 PM
	Paratek Pharmaceuticals (PRTK) to Release Earnings on Wednesday www.americanbankingnews.com - April 25 at 6:32 AM
	Paratek Pharmaceuticals (PRTK) Downgraded by BidaskClub to Strong Sell www.americanbankingnews.com - April 24 at 9:58 AM
	Paratek's omadacycline on par with moxifloxacin in late-stage study in CABP seekingalpha.com - April 23 at 4:36 PM
	Paratek Pharmaceuticals (PRTK) Prices $140 Million of Convertible Senior Subordinated Notes due 2024 www.streetinsider.com - April 20 at 9:23 AM
	Here's Why Paratek Pharmaceuticals Dropped as Much as 16.6% Today www.msn.com - April 19 at 4:49 PM
	Here's Why Paratek Pharmaceuticals Dropped as Much as 16.6% Today finance.yahoo.com - April 19 at 4:49 PM
	Paratek Pharmaceuticals (PRTK) Announces Proposed Private Offering of $125 Million of Convertible Senior Subordinated Notes due 2024 www.streetinsider.com - April 19 at 9:11 AM
	Paratek Pharmaceuticals, Inc. Prices $140 Million of Convertible Senior Subordinated Notes due 2024 finance.yahoo.com - April 19 at 9:11 AM
	Paratek Pharma launches $125M convertible debt offering seekingalpha.com - April 18 at 4:54 PM
	Paratek Pharmaceuticals, Inc. Announces Proposed Private Offering of $125 Million of Convertible Senior Subordinated Notes due 2024 finance.yahoo.com - April 18 at 4:54 PM
	Brokers Set Expectations for Paratek Pharmaceuticals, Inc.'s Q1 2018 Earnings (PRTK) www.americanbankingnews.com - April 18 at 7:52 AM
	Paratek Pharmaceuticals, Inc. (PRTK) Receives Average Recommendation of "Buy" from Analysts www.americanbankingnews.com - April 18 at 3:21 AM
	Paratek Pharmaceuticals (PRTK) Price Target Raised to $43.00 www.americanbankingnews.com - April 17 at 7:34 PM
	Analysts Offer Predictions for Paratek Pharmaceuticals, Inc.'s FY2020 Earnings (PRTK) www.americanbankingnews.com - April 17 at 7:05 AM
	BidaskClub Downgrades Paratek Pharmaceuticals (PRTK) to Buy www.americanbankingnews.com - April 16 at 5:24 PM
	Technical Perspectives on Biotech Stocks -- Pain Therapeutics, Paratek Pharma, PDL BioPharma, and Progenics ... www.prnewswire.com - April 16 at 9:07 AM
	BRIEF-Paratek Appoints Rolf Hoffman To Co's Board Of Directors www.reuters.com - April 14 at 4:25 PM
	Paratek Pharmaceuticals (PRTK) Names Rolf K. Hoffman to Board www.streetinsider.com - April 14 at 4:25 PM
	Paratek Pharmaceuticals (PRTK) Rating Increased to Sell at BidaskClub www.americanbankingnews.com - April 14 at 10:43 AM
	Paratek Appoints Rolf K. Hoffman to Company’s Board of Directors finance.yahoo.com - April 14 at 9:22 AM
	Paratek Pharmaceuticals Presenting New Data from Omadacycline Development Program at ECCMID 2018 finance.yahoo.com - April 12 at 10:03 AM
	Evan Loh Sells 8,084 Shares of Paratek Pharmaceuticals Inc (PRTK) Stock www.americanbankingnews.com - April 10 at 10:16 PM
	Paratek Pharmaceuticals Inc (PRTK) Chairman Michael Bigham Sells 8,700 Shares www.americanbankingnews.com - April 10 at 10:16 PM
	Insider Selling: Paratek Pharmaceuticals Inc (PRTK) VP Sells 5,700 Shares of Stock www.americanbankingnews.com - April 10 at 10:16 PM
	Douglas W. Pagan Sells 5,237 Shares of Paratek Pharmaceuticals Inc (PRTK) Stock www.americanbankingnews.com - April 10 at 10:16 PM
	Paratek Pharmaceuticals (PRTK) Upgraded to Buy by BidaskClub www.americanbankingnews.com - April 10 at 8:55 PM
	Paratek Pharmaceuticals (PRTK) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow seekingalpha.com - April 10 at 4:40 PM
	Paratek Pharmaceuticals (PRTK) Now Covered by Analysts at Guggenheim www.americanbankingnews.com - April 5 at 8:30 PM
	Paratek's (PRTK) NDA for Oral and Intravenous Omadacycline Accepted for Priority Review by FDA www.streetinsider.com - April 5 at 4:37 PM

Paratek Pharmaceuticals (NASDAQ:PRTK) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Paratek Pharmaceuticals (NASDAQ:PRTK) Income Statement, Balance Sheet and Cash Flow Statement

Paratek Pharmaceuticals (NASDAQ PRTK) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff